SightStream Biotherapeutics, Inc. — Form D/A
SightStream Biotherapeutics, Inc. of WALPOLE, MA, a company, filed a Form D amendment with the SEC on 2023-06-12. The offering totals $3.5M, of which $3.1M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2023-06-12
- Form: D/A
- Accession: 0001932386-23-000002
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $3.5M
- Amount sold: $3.1M
- Remaining: $435K
- Investors: 21
- Date of first sale: 2022-05-25
- Revenue range: Decline to Disclose
- SEC file number: 021-448088
Issuer
- Name: SightStream Biotherapeutics, Inc.
- CIK: 0001932386
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2020
- Address: 55 WEST STREET, SUITE 201, WALPOLE, MA, 02081
- Phone: 617-388-2635
Officers, directors & promoters (7)
| Name | Role | Location |
|---|
| Samuel Wu | Director | Walpole, MA |
| Wenkai Xiang | Director | Walpole, MA |
| David Neafus | Executive Officer | Walpole, MA |
| Reza Dana | Director | Half Moon Bay, CA |
| Jason Werner | Director | Walpole, MA |
| Jason Werner | Executive Officer | Walpole, MA |
| Jiagang Zhao | Director | Medfield, MA |
Other filings by this issuer (5)
More